Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup

European Journal of Cancer

Volumn 48, Issue 5, 2012, Pages 703-712

  McTiernan, Anne ^a   Jinks, Rachel C ^b   Sydes, Matthew R ^b   Uscinska, Barbara ^b   Hook, Jane M ^b   Van Glabbeke, Martine ^c   Bramwell, Vivien ^d   Lewis, Ian J ^e   Taminiau, Antonie H M ^f   Nooij, Marianne A ^f   Hogendoorn, Pancras C W ^f   Gelderblom, Hans ^f   Whelan, Jeremy S ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c EORTC DATA CENTER   (Belgium)

^d TOM BAKER CANCER CENTRE   (Canada)

^e ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Osteosarcoma; Survival; Toxicity

Indexed keywords

CISPLATIN; DOXORUBICIN;

ADOLESCENT; ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CHONDROSARCOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; INFECTION; LEUKOPENIA; LIMB TUMOR; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; OSTEOSARCOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SCHOOL CHILD; SMALL CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858703999     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.09.012     Document Type: Article

References (26)

1. G. Bacci, A. Longhi, and M. Versari Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution Cancer 106 2006 1154 1161
2. S.S. Bielack, B. Kempf-Bielack, and G. Delling Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols J Clin Oncol 20 2002 776 790 (Pubitemid 34111386)
3. A.M. Davis, R.S. Bell, and P.J. Goodwin Prognostic factors in osteosarcoma: a critical review J Clin Oncol 12 1994 423 431 (Pubitemid 24056419)
4. R.L. Souhami, A.W. Craft, and J.W. Van der Eijken Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup Lancet 350 1997 911 917 (Pubitemid 27420527)
5. E.I. Hauben, S. Weeden, J. Pringle, E.A. Van Marck, and P.C. Hogendoorn Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup Eur J Cancer 38 2002 1218 1225 (Pubitemid 34603483)
6. T. Yamanaka, S. Matsumoto, and S. Teramukai Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma Br J Cancer 97 2007 37 42 (Pubitemid 47012089)
7. U. Banerji, S. Ashley, and J. Coward The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer Lung cancer 54 2006 371 377 (Pubitemid 44634135)
8. M. Di Maio, C. Gridelli, and C. Gallo Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials Lancet Oncol 6 2005 669 677 (Pubitemid 41222757)
9. E.M. Rankin, L. Mill, and S.B. Kaye A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer Br J Cancer 65 1992 275 281
10. G. Dolan, J.S. Lilleyman, and S.M. Richards Prognostic importance of myelosuppression during maintenance treatment of lymphoblastic leukaemia. Leukaemia in Childhood Working Party of the Medical Research Council Arch Dis Child 64 1989 1231 1234 (Pubitemid 19220765)
11. K. Schmiegelow, M.K. Pulczynska, and M. Seip White cell count during maintenance chemotherapy for standard-risk childhood acute lymphoblastic leukemia: relation to relapse rate Pediatr Hematol Oncol 5 1988 259 267
12. I. Ray-Coquard, C. Cropet, and M. Van Glabbeke Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas Cancer Res 69 2009 5383 5391
13. V.H. Bramwell, M. Burgers, and R. Sneath A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup J Clin Oncol 10 1992 1579 1591 (Pubitemid 23057988)
14. I.J. Lewis, M.A. Nooij, and J. Whelan Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup J Natl Cancer Inst 99 2007 112 128
15. I.J. Lewis, S. Weeden, D. Machin, D. Stark, and A.W. Craft Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup J Clin Oncol 18 2000 4028 4037 (Pubitemid 32038394)
16. World Health Organisation. Handbook for reporting results of cancer treatment. Geneva: World Health Organisation; 1979.
17. M.K.B. Parmar, and D. Machin Survival analysis: a practical approach 1995 J. Wiley Chichester, New York
18. P. Poikonen, T. Saarto, J. Lundin, H. Joensuu, and C. Blomqvist Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF Br J Cancer 80 1999 1763 1766 (Pubitemid 29389629)
19. G. Bacci, L. Loro, and A. Longhi No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma Anticancer Drugs 17 2006 411 415 (Pubitemid 44309983)
20. G. Bacci, S. Ferrari, and N. Delepine Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin J Clin Oncol 16 1998 658 663 (Pubitemid 28135613)
21. N. Graf, K. Winkler, M. Betlemovic, N. Fuchs, and U. Bode Methotrexate pharmacokinetics and prognosis in osteosarcoma J Clin Oncol 12 1994 1443 1451 (Pubitemid 24206244)
22. K.R. Crews, T. Liu, and C. Rodriguez-Galindo High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma Cancer 100 2004 1724 1733 (Pubitemid 38456352)
23. Windsor RE, Kallis C, Strauss SJ, Wood N, Whelan JS. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer, in press. doi: 10.1002/cncr.26472.
24. C. Moore, D. Eslin, and A. Levy Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma Pediatr Blood Cancer 55 2010 1096 1102
25. G. De Angulo, M. Hernandez, and J. Morales-Arias Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma J Pediatr Hematol Oncol 29 2007 48 52 (Pubitemid 46143025)
26. N. Marina, S. Bielack, and J. Whelan International collaboration is feasible in trials for rare conditions: the EURAMOS experience Cancer Treat Res 152 2009 339 353